Biogen (BIIB) Tops Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
October 26, 2016 6:59 AM EDTThird quarter 2016 GAAP diluted EPS rise 13%; Non-GAAP diluted EPS rise 16%
Nusinersen filed with FDA and EMA for spinal muscular atrophy based on positive interim analysis of ENDEAR trial
Phase 3 Alzheimers disease candidate aducanumab receives FDA Fast Track designation
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including:
Total revenues of $3.0 billion, a 6% increase versus the same quarter in the prior year. Growth was driven by a 10% increase in worldwide TECFIDERA®... More